Gastrointestinal Tract - Original Article

Levels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease

Volume 30 · Issue 12 Publish Date: December 15, 2019
Bilgehan Yüzbaşıoğlu Müge Ustaoğlu Şule Yüzbaşıoğlu Ulaş Emre Akbulut Kamil Özdil
Full Text PDF
DOI

Published In

Turkish Journal of Gastroenterology

Volume 30 · Issue 12

Pages: 1025-1029

History

Published Online: December 15, 2019

Copyright © 2019 Bilgehan Yüzbaşıoğlu, Müge Ustaoğlu, Şule Yüzbaşıoğlu, Ulaş Emre Akbulut, Kamil Özdil

Bilgehan Yüzbaşıoğlu
Department of Gastroenterology, Bursa State Hospital, Bursa, Turkey
Müge Ustaoğlu
Department of Gastroenterology, Trabzon Kanuni Training and Research Hospital, Trabzon, Turkey
Şule Yüzbaşıoğlu
Department of Hematology, Bursa Higher Specialization Training and Research Hospital, Bursa, Turkey
Ulaş Emre Akbulut
Department of Pediatric Gastroenterology Hepatology and Nutrition, Kanuni Training and Research Hospital, Trabzon, Turkey
Kamil Özdil
Department of Gastroenterology, Ümraniye Training and Research Hospital, İstanbul
Yüzbaşıoğlu, B., Ustaoğlu, M., Yüzbaşıoğlu, Şule, Akbulut, U. E., & Özdil, K. (2019). Levels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease. Turkish Journal of Gastroenterology, 30(12), 1025–1029. https://doi.org/10.5152/tjg.2019.19346
Endnote/Zotero/Mendeley (RIS) BibTeX
Full Text Full Text PDF

Abstract

Background/Aims: There is an increased tendency for thrombosis and thromboembolic complications in patients with inflammatory bowel disease (IBD). The aim of the present study was to determine the serum concentrations of thrombin-activatable fibrinolysis inhibitor (TAFI), tissue factor pathway inhibitor (TFPI) and a disintegrin and metalloproteinase with thrombospondin motif-13 (ADAMTS-13) in patients with IBD and to assess their possible role in the etiopathogenesis of the disease. Materials and Methods: Thirty-four patients with IBD (23 ulcerative colitis and 11 Crohn’s disease) and 20 healthy controls were included in the present study. TAFI, TFPI, and ADAMTS-13 concentrations were determined by enzyme-linked immunosorbent assay. Results: Mean TAFI, TFPI, and ADAMTS-13 concentrations in the patient group were 17.75 ng/ml, 72.10 ng/ml, and 14.90 U/l, respectively. In the control group, these values were 117.10 ng/ml, 300 ng/ml, and 191.55 U/l, respectively. TAFI, TFPI, and ADAMTS-13 values were significantly lower in the patient group than in the control group (all p<0.01). Conclusion: TAFI, TFPI, and ADAMTS-13 levels were significantly lower in the patient group. These findings indicate the presence of a clear, multifactorial imbalance in the coagulation–fibrinolytic system in the patient group. It is also possible that this imbalance in the coagulation and fibrinolytic system may play a role in the still unclear etiopathogenesis of the disease.

Most read articles by the same author(s)

1 2 > >> 
Article Info
Published In
Journal Turkish Journal of Gastroenterology
Volume / Issue Volume 30 · Issue 12
Pages 1025-1029
DOI 10.5152/tjg.2019.19346
History
Published Online December 15, 2019
Copyright
Copyright (c) 2019 Bilgehan Yüzbaşıoğlu, Müge Ustaoğlu, Şule Yüzbaşıoğlu, Ulaş Emre Akbulut, Kamil Özdil
Affiliations
Bilgehan Yüzbaşıoğlu
Department of Gastroenterology, Bursa State Hospital, Bursa, Turkey
Müge Ustaoğlu
Department of Gastroenterology, Trabzon Kanuni Training and Research Hospital, Trabzon, Turkey
Şule Yüzbaşıoğlu
Department of Hematology, Bursa Higher Specialization Training and Research Hospital, Bursa, Turkey
Ulaş Emre Akbulut
Department of Pediatric Gastroenterology Hepatology and Nutrition, Kanuni Training and Research Hospital, Trabzon, Turkey
Kamil Özdil
Department of Gastroenterology, Ümraniye Training and Research Hospital, İstanbul
Cite this Article
Yüzbaşıoğlu, B., Ustaoğlu, M., Yüzbaşıoğlu, Şule, Akbulut, U. E., & Özdil, K. (2019). Levels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease. Turkish Journal of Gastroenterology, 30(12), 1025–1029. https://doi.org/10.5152/tjg.2019.19346
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX
Outlines